+1 (855) PLE.XISION (753.9474) info@plexision.com


You are here


Plexision’s pipeline as based on two classes of patented or patent-pending, high-resolution cell-based test systems. These test systems detect respectively, the patient’s immune system’s inflammatory response to the pathogen or affinity to the pathogen.


  • The PlexEBV blood test measures cell-based immunity to the Epstein-Barr virus (EBV).
  • EBV infects most people at some time in their lives (www.cdc.gov). EBV persists in the body after the initial infection and can reactivate in individuals with immune systems, which have been weakened by disease and immunosuppressive drugs.
  • In some transplant patients, EBV can persist at high levels in the blood and is accompanied by the development of EBV-driven lymphoma.
  • Reducing immunosuppression can help lower EBV levels in blood, but fails to do so in some patients and can cause rejection in others
  • EBV infection is accompanied by loss of cell-based immunity to the EBV.
  • Knowledge about immunity to EBV can help physicians determine when to start, stop or continue therapy for EBV.


  • The PlexABMR test measures the risk of rejection in which B-cells play a major role by producing antibodies against the transplanted organ.
  • Antibody-mediated rejection (ABMR) is a less common form of rejection compared with cellular rejection, but has been linked to accelerated graft loss.
  • Antibody-mediated rejection can accompany cellular rejection, requires different drugs than cellular rejection, and is not easily distinguished from acute cellular rejection.
  • Information about the risk of ABMR can improve drug selection prevention and treatment and improve graft health and longevity.